Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer

Table 1 Cohort characteristics

Characteristic	Lung cancer n (%) (n = 60 ^b)	Controls n (%) (n = 16)^d	Lung cancer vs controls, p-value	Total N (%) (N = 76)
Age			0.126
Median	72	75		72
Range	39–85	49–84		39–85
Sex			0.835
Male	32 (53.3)	9 (56.3)		40 (52.6)
Female	28 (46.7)	7 (43.8)		36 (47.4)
Smoking			0.391
Never	12 (20.0)	6 (37.5)		19 (25.0)
Former	29 (48.3)	6 (37.5)		34 (44.7)
Current	19 (31.7)	4 (25.0)		23 (30.3)
Histology
AC	37 (61.7)			37 (48.7)
SqCC	15 (25.0)			15 (19.7)
SCLC	8 (13.3)			8 (10.5)
Controls				16 (21.1)
Stage
I–IIIa	19 (31.7)
IIIb–IV	41^c (68.3)
ECOG PS
PS 0	15 (25.0)
PS 1	24 (40.0)
PS 2	12 (20.0)
PS 3–4^a	9 (15.0)
Treatment
Surgery	9 (15.0)
Radiation	9 (15.0)
Chemotherapy	23 (38.3)
Targeted therapy or immunotherapy	10 (16.7)
Best supportive care/no treatment	9 (15.0)

Controls consisted of patients referred to the lung clinic with the suspicion of lung cancer but later diagnosed with different benign lung diseases
AC adenocarcinoma, SqCC squamous cell carcinoma, SCLC small cell lung cancer, ECOG PS Eastern cooperative oncology group performance status
^aOne patient had PS 4
^bOne cfDNA sample was excluded due to low unique molecular depth
^cFive patients had stage IIIb
^dControls with benign lung disease were diagnosed with different types of inflammation, fibrosis and noduli in and around the lung tissue

ISSN: 1528-3658